1. Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133+ bone marrow stem cell transplant 
Can Yerebakan, MD, Alexander Kaminski, MD, Bernd Westphal, MD, Peter Donndorf, MD, Aenne Glass, PhD, Andreas Liebold, MD, Christof Stamm, MD, Gustav Steinhoff, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 142, Issue 6, Pages e3 (December 2011)
DOI: /j.jtcvs
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
Kaplan-Meier survival curve for stem cell–treated group (blue) and control group (red).
The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs )
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
Comparisons of functional outcomes. A, Minnesota Living With Heart Failure Questionnaire (MLHFQ) scores in the stem cell group (n = 26) and the control group (n = 14) at long-term follow-up. Preoperative Minnesota Living With Heart Failure Questionnaire scores of the groups were not available. B, New York Heart Association (NYHA) functional class values in the stem cell group (n = 34) and the control group (n = 13) both preoperatively (Pre) and at long-term follow-up (LTFU). Asterisk indicates P < .05 versus preoperative value.
The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs )
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

4. Figure 3
A, Comparison of all patients from the stem cell and control groups who underwent echocardiographic evaluation in the long-term follow-up (LTFU) with respect to left ventricular ejection fraction (LVEF) improvement during the follow-up period. B, Left ventricular ejection fraction (LVEF) course of a subgroup of patients in both groups with a preoperative left ventricular ejection fraction not more than 40% is compared between the stem cell group (n = 9) and the control group (n = 7). C, Comparison between the stem cell and control groups of the improvement in the left ventricular ejection fraction (LVEF) in the long-term follow-up relative to the preoperative left ventricular ejection fraction for the subgroup of patients with a preoperative left ventricular ejection fraction not greater than 40%. Long-term follow-ups were 65 ± 21 months and 62 ± 9 months for the stem cell group and the control group, respectively. Asterisk indicates P < .05 versus preoperative; dagger indicates P < .05 versus control group.
The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs )
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

5. Figure E1
Representative single-photon emission computed tomographic scans of a patient from the stem cell group who underwent bypass grafting to the left anterior descending, circumflex, and right coronary arteries, as well as the injection of 6 × 106 CD133-selected CD34+ cells in the posteroinferior area of myocardial infarction. At discharge (2 weeks), tracer activity in the infarct area was still diminished; however, perfusion had virtually returned to normal at 3 months and showed sustained superior perfusion at 3 years relative to preoperative activity in the area of stem cell injection.
The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs )
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions